- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Conor Killmurray | Authors
Articles
CG0070 Provides Durable Responses in Certain Patients with Non-Muscle Invasive Bladder Cancer
June 21, 2022
Article
In an interview with Targeted Oncology, Roger Li, MD, discussed the use of the CG0070 in combination with pembrolizumab and nivolumab for patients with non-muscle invasive bladder cancer who are unresponsive to Bacillus Calmette-Guerin.
Post hoc Analysis of CLEAR Trial Shows Comparable OS Regardless of Subsequent Therapy in aRCC
June 15, 2022
Article
Results from the phase 3 CLEAR trial showed lenvatinib plus everolimus to have a statistically significant improvement in progression-free survival and objective response rate compared with those given sunitinib.
Real-World Data Show Survival Benefit With Larotrectinib vs Standard of Care in TRK Fusion–Positive Tumors
June 07, 2022
Article
At the 2022 ASCO Annual Meeting, utilizing matching-adjusted indirect comparison, researchers showed the survival benefit of larotrectinib in patients with TRK fusion-positive tumors.
Sugemalimab Plus Chemotherapy Demonstrates Durable Efficacy as First-Line Treatment in Metastatic NSCLC
June 07, 2022
Article
At the 2022 ASCO Annual Meeting, results from the GEMSTONE-302 trial showed that adding sugemalimab to chemotherapy improved survival in patients with metastatic non–small cell lung cancer.
Lisocabtagene Maraleucel Is a Durable Second-line Therapy for Certain Patients with R/R Large B-Cell Lymphoma
June 05, 2022
Article
At the 2022 ASCO Annual Meeting, the primary analysis of the phase 2 PILOT study showed the durability and feasibility of lisocabtagene maraleucel as second-line therapy in certain patients with large B-cell lymphoma.
ESMO Makes New Guidelines for Classifying Research Into De-Intensification of Cancer Treatments
May 23, 2022
Article
The European Society of Medical Oncology has announced the development of a new evidence-based classification framework to guide research and interpretation of data on the de-intensification of cancer treatments.